Vertex Pharmaceuticals Incorporated (VRTX)

NasdaqGS • Currently down 6.90 (-1.60%) in today's trading session

3 members of Congress have disclosed 10 trades in Vertex Pharmaceuticals Incorporated (VRTX) via STOCK Act filings. The most recent disclosure was a sale by David J. Taylor on 29 January 2026. The most active traders have been Lisa McClain (4), Byron Donalds (4), and David J. Taylor (2). Aggregate disclosed activity totals roughly $40K in purchases and $40K in sales (midpoint estimates from bracketed disclosure amounts).

Vertex Pharmaceuticals Incorporated is currently trading at $423.24, positioned at 41% of its 52-week range ($362.50 – $509.00).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Free asset at sign up • Eligible regions only
Copy PortfolioClaim Free Asset
Live portfolio tracking
Automatic rebalancing

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Not available in the US.

Past Performance is not an indication of future results.

*Free asset promotion available at sign up in eligible regions only. Terms and conditions apply.

Current Price
$423.24
24h Change
-6.90 (-1.60%)
52 Week Range
$362.50—$509.00
View on NASDAQ

Vertex Pharmaceuticals Incorporated Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for VRTX

Select to highlight on chart
4 transactions
Compliance: 40%
David J. Taylor29 Jan 20262 Feb 2026SaleStock$1,001 - $15,000N/A
David J. Taylor7 Aug 20252 Sept 2025PurchaseStock$1,001 - $15,000+9.75%
Byron Donalds20 Mar 202514 Apr 2025SaleStock$1,001 - $15,000N/A
Byron Donalds20 Mar 202514 Apr 2025SaleStock$1,001 - $15,000N/A

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$107.66B

Volume

1.06M

Beta

0.37

P/E Ratio

27.63

Fundamentals

EPS

$15.32

Div. Yield

—

Open

$424.44

Day Range

$419.71 — $426.72

Company Information

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ · USD
Country
US
CEO
Reshma Kewalramani
IPO Date
1991-07-24
Website
www.vrtx.com

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have...

Earnings

Next Report

Q1 2026

4 May

EPS Est.

$4.26

Rev. Est.

$3B

Days Until

4

Recent Quarters

Q4 202512 Feb
EPS$5.03
Miss 1.6%
Q3 20253 Nov
EPS$4.80
Beat 5.0%
Q2 20254 Aug
EPS$4.52
Beat 5.4%
Q1 20255 May
EPS$4.06
Miss 4.5%
Q4 202410 Feb
EPS$3.98
Miss 1.0%
Q3 20244 Nov
EPS$4.38
Beat 5.8%
Q2 20241 Aug
EPS$-12.83
Miss 10.3%
Q1 20246 May
EPS$4.76
Beat 17.2%
Q4 20235 Feb
EPS$4.20
Beat 2.4%
Q3 20236 Nov
EPS$4.08
Beat 2.8%
Q2 20231 Aug
EPS$3.89
Beat 0.3%
Q1 20231 May
EPS$3.05
Beat 1.7%
Q4 20227 Feb
EPS$3.76
Beat 7.1%
Q3 202227 Oct
EPS$4.01
Beat 10.2%
Q2 20224 Aug
EPS$3.60
Beat 3.5%
Q1 20225 May
EPS$3.52
Beat 0.9%
Q4 202126 Jan
EPS$3.37
Beat 2.1%
Q3 20212 Nov
EPS$3.56
Beat 15.6%
Q2 202129 Jul
EPS$3.11
Beat 15.6%
Q1 202129 Apr
EPS$2.98
Beat 10.8%
Q4 20201 Feb
EPS$2.51
Miss 3.1%
Q3 202029 Oct
EPS$2.64
Beat 12.8%
Q2 202030 Jul
EPS$2.61
Beat 26.1%
Q1 202029 Apr
EPS$2.56
Beat 38.4%
Q4 201930 Jan
EPS$1.70
Beat 40.5%
Q3 201930 Oct
EPS$1.23
Beat 7.9%
Q2 201931 Jul
EPS$1.26
Beat 17.8%
Q1 201930 Apr
EPS$1.14
Beat 17.5%
Q4 20185 Feb
EPS$1.30
Beat 23.8%
Q3 201824 Oct
EPS$1.09
Beat 9.0%
Q2 201825 Jul
EPS$0.94
Beat 25.3%
Q1 201826 Apr
EPS$0.76
Beat 20.6%
Q4 201731 Jan
EPS$0.61
Beat 5.2%
Q3 201725 Oct
EPS$0.53
Beat 43.2%
Q2 201726 Jul
EPS$0.39
Beat 11.4%
Q1 201727 Apr
EPS$0.41
Beat 41.4%
Q4 201625 Jan
EPS$0.35
Beat 34.6%
Q3 201625 Oct
EPS$0.16
Miss 15.8%
Q2 201627 Jul
EPS$0.24
Beat 9.1%
Q1 201627 Apr
EPS$0.09
Miss 66.7%
Q4 201527 Jan
EPS$0.17
Beat 21.4%
Q3 201528 Oct
EPS$-0.13
Beat 53.6%
Q2 201529 Jul
EPS$-0.54
Beat 14.3%
Q1 201529 Apr
EPS$-0.62
Beat 17.3%
Q4 201428 Jan
EPS$-0.73
Miss 19.7%
Q3 201428 Oct
EPS$-0.37
Beat 31.5%
Q2 201429 Jul
EPS$-0.61
Beat 20.8%
Q1 20141 May
EPS$-0.65
Beat 7.1%
Q4 201329 Jan
EPS$-0.56
Miss 24.4%
Q3 201329 Oct
EPS$-0.32
Beat 17.9%
Q2 201329 Jul
EPS$-0.03
Beat 85.7%
Q1 201330 Apr
EPS$0.03
Beat 117.7%
Q4 201229 Jan
EPS$0.04
Beat 133.3%
Q3 20121 Nov
EPS$0.13
Miss 23.5%
Q2 201230 Jul
EPS$0.46
Miss 20.7%
Q1 201226 Apr
EPS$0.43
Miss 23.2%
Q4 20112 Feb
EPS$0.74
Beat 5.7%
Q3 201127 Oct
EPS$1.02
Beat 385.7%
Q2 201128 Jul
EPS$-0.85
Beat 11.5%
Q1 20113 May
EPS$-0.91
Beat 16.5%
Q4 20103 Feb
EPS$-0.90
Beat 3.2%
Q3 201025 Oct
EPS$-1.04
Miss 11.8%
Q2 201028 Jul
EPS$-1.00
Miss 19.1%
Q1 201021 Apr
EPS$-0.83
Miss 3.8%
Q4 20094 Feb
EPS$-0.85
Beat 0.0%
Q3 200926 Oct
EPS$-0.84
Miss 2.4%
Q2 20095 Aug
EPS$-0.99
Miss 17.9%
Q1 200916 Apr
EPS$-1.04
Miss 26.8%
Q4 20089 Feb
EPS$-0.96
Miss 3.2%
Q3 200827 Oct
EPS$-0.93
Miss 1.1%
Q2 200831 Jul
EPS$-0.66
Miss 15.8%
Q1 200821 Apr
EPS$-0.72
Miss 10.8%
Q4 200711 Feb
EPS$-0.66
Beat 0.0%
Q3 200729 Oct
EPS$-0.82
Miss 12.3%
Q2 200724 Jul
EPS$-0.91
Miss 31.9%
Q1 200730 Apr
EPS$-0.64
Beat 0.0%
Q4 20061 Feb
EPS$-0.22
Beat 42.1%
Q3 200626 Oct
EPS$-0.46
Beat 4.2%
Q2 200626 Jul
EPS$-0.72
Miss 38.5%
Q1 200625 Apr
EPS$-0.47
Beat 16.1%
Q4 20057 Feb
EPS$-0.38
Miss 65.2%
Q3 200526 Oct
EPS$-0.84
Miss 78.7%
Q2 200527 Jul
EPS$-0.50
Beat 2.0%
Q1 200526 Apr
EPS$-0.56
Beat 0.0%
Q4 20049 Feb
EPS$-0.54
Miss 22.7%
Q3 200425 Oct
EPS$-0.49
Miss 2.1%
Q2 200426 Jul
EPS$-0.56
Miss 9.8%
Q1 200426 Apr
EPS$-0.52
Beat 0.0%
Q4 200311 Feb
EPS$-0.51
Beat 5.6%
Q3 200310 Nov
EPS$-0.58
Miss 18.4%
Q2 200324 Jul
EPS$-0.60
Beat 1.6%
Q1 200324 Apr
EPS$-0.64
Miss 33.3%
Q4 20024 Feb
EPS$-0.40
Beat 0.0%
Q3 20024 Nov
EPS$-0.44
Miss 46.7%
Q2 200218 Jul
EPS$-0.28
Beat 0.0%
Q1 200224 Apr
EPS$-0.29
Miss 3.6%
Q4 20017 Feb
EPS$-0.15
Beat 21.1%
Q3 200124 Oct
EPS$-0.18
Beat 33.3%
Q2 200127 Jul
EPS$-0.16
Beat 38.5%
Q1 200124 Apr
EPS$-0.15
Beat 51.6%
Q4 200022 Feb
EPS$-0.04
Beat 71.4%
Q3 200024 Oct
EPS$-0.46
Miss 109.1%
Q2 200026 Jul
EPS$0.22
Beat 4.8%
Q1 200011 May
EPS$-0.31
Miss 6.9%
Q4 199916 Feb
EPS$0.03
Beat 425.4%
Q3 199927 Oct
EPS$-0.28
Miss 12.0%
Q2 199927 Jul
EPS$-0.21
Miss 10.5%
Q1 199921 Apr
EPS$-0.34
Miss 13.3%
Q4 199825 Feb
EPS$-0.25
Miss 19.1%
Q3 199821 Oct
EPS$-0.04
Beat 55.6%
Q2 199822 Jul
EPS$-0.19
Miss 26.7%
Q1 199822 Apr
EPS$-0.16
Beat 0.0%
Q4 199723 Feb
EPS$-0.13
Beat 13.3%
Q3 199721 Oct
EPS$-0.11
Beat 21.4%
Q2 199722 Jul
EPS$-0.03
Beat 75.0%
Q1 199722 Apr
EPS$-0.13
Beat 13.3%
Q4 199619 Feb
EPS$-0.09
Beat 43.8%
Q3 199623 Oct
EPS$-0.16
Beat 15.8%
Q2 199626 Jul
EPS$-0.21
Miss 16.7%
Q1 199625 Apr
EPS$-0.21
Miss 23.5%
Q4 199522 Feb
EPS$-0.02
Beat 77.8%
Q3 199525 Oct
EPS$-0.20
Miss 25.0%
Q2 199526 Jul
EPS$-0.26
Miss 85.7%
Q1 199527 Apr
EPS$-0.13
Beat 23.5%
Q4 199415 Feb
EPS$-0.15
Beat 11.8%
Q3 199421 Oct
EPS$-0.12
Beat 7.7%
Q2 199421 Jul
EPS$-0.17
Miss 54.5%
Q1 199425 Apr
EPS$-0.11
Beat 8.3%
Q4 199311 Feb
EPS$0.35
Beat 333.3%
Q3 199331 Dec
EPS$0.30
Q2 199322 Jul
EPS$-0.03
Q1 199319 May
EPS$-0.13
Beat 7.1%
Q4 199210 Feb
EPS$-0.11
Miss 266.7%
Q3 199231 Dec
EPS$-0.11
Q1 199230 Jun
EPS$-0.08
Q4 199131 Mar
EPS$-0.07
Q3 199131 Dec
EPS$-0.06
Q3 199131 Dec
EPS$-0.09
Q2 199130 Sept
EPS$-0.07
Q1 199130 Jun
EPS$-0.07
Q3 199031 Dec
EPS$-0.08
Q3 199031 Dec
EPS$-0.08
Q3 199031 Dec
EPS$-0.08
Q3 199031 Dec
EPS$-0.08

1 politician traded within 30 days

No dividend data available for this stock.

Stock Splits

Split History

24 Aug 2000Stock Split
Ratio2:1

Similar Stocks

Based on congressional trading patterns

Smart Recommendations

MCK

McKesson Corporation

61
$822.63-12.37 (-1.48%)
Healthcare
2 politicians both hold this
Same sector: Healthcare
2 politicians
View Stock

V

Visa Inc.

46
$334.86+25.56 (+8.26%)
Financial Services
3 politicians hold this stock
3 politicians
View Stock

MSFT

Microsoft Corporation

46
$424.46-4.79 (-1.12%)
Technology
3 politicians hold this stock
3 politicians
View Stock

Frequently Asked Questions about VRTX

Which members of Congress have traded VRTX?
3 members of Congress have disclosed 10 trades in Vertex Pharmaceuticals Incorporated (VRTX) under the STOCK Act. The most active traders are Lisa McClain, Byron Donalds, and David J. Taylor.
When was VRTX most recently disclosed by Congress?
The most recent VRTX disclosure was a sale by David J. Taylor on 29 January 2026.
What is the total disclosed congressional trading volume for VRTX?
Members of Congress have disclosed approximately $40K in VRTX purchases and $40K in sales. These figures are midpoint estimates derived from the bracketed amount ranges used in STOCK Act filings.
How can I track new congressional trades in VRTX?
This VRTX page updates as soon as new STOCK Act disclosures are filed for Vertex Pharmaceuticals Incorporated. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi TrackerJoin our Discord
PoliticiansPortfoliosPricingLegalTerms of ServicePrivacy Policy
Français
© 2026 - All rights reserved. Powered by Vantara Labs
This website is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office, or her representatives. Any use of her name is solely for the purpose of discussing publicly available information.The information provided on this website is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.